Medulloblastoma in a Child with Fragile X Syndrome

George A. Alexiou; George Siozos; Kalliopi Stefanaki; Eustathios Vlachakis; George Sfakianos; Neofytos Prodromou; Maria Moschovi

doi:10.1055/s-0032-1315430

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2012; 43(03): 155-158
DOI: 10.1055/s-0032-1315430

Short Communication

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medulloblastoma in a Child with Fragile X Syndrome

Authors

George A. Alexiou

¹Department of Neurosurgery, Children's Hospital “Agia Sofia,” Athens, Greece
George Siozos

²Department of Pathology, Children's Hospital “Agia Sofia,” Athens, Greece
Kalliopi Stefanaki

²Department of Pathology, Children's Hospital “Agia Sofia,” Athens, Greece
Eustathios Vlachakis

¹Department of Neurosurgery, Children's Hospital “Agia Sofia,” Athens, Greece
George Sfakianos

¹Department of Neurosurgery, Children's Hospital “Agia Sofia,” Athens, Greece
Neofytos Prodromou

¹Department of Neurosurgery, Children's Hospital “Agia Sofia,” Athens, Greece
Maria Moschovi

³Department of Hematology Oncology, Unit of 1st Department of Pediatrics of Athens University, Children's Hospital “Agia Sofia,” Athens, Greece

Abstract

Fragile X syndrome is the most common cause of inherited intellectual impairment and has been associated with decreased incidence of cancer. We present the case of an 11-year-old boy with a diagnosis of fragile X syndrome who presented with gait imbalance, headache, and episodes of vomiting. Radiological investigation revealed the presence of a posterior fossa tumor. The patient was operated upon and the tumor proved to be a medulloblastoma (MB). To the best of our knowledge this is the first reported case of MB in a child with fragile X syndrome.

Keywords

medulloblastoma - fragile X syndrome - children

Volltext

Referenzen

References
1 Alexiou GA, Moschovi M, Stefanaki K, Sfakianos G, Prodromou N ; Experience from the Agia Sofia Children's Hospital. Epidemiology of pediatric brain tumors in Greece (1991-2008). Cent Eur Neurosurg 2011; 72 (1) 1-4
2 Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 2008; 65 (11) 1419-1424
3 Moschovi M, Sotiris Y, Prodromou N , et al. Familial medulloblastoma. Pediatr Hematol Oncol 1998; 15 (5) 421-424
4 O'Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002; 25: 315-338
5 Kalkunte R, Macarthur D, Morton R. Glioblastoma in a boy with fragile X: an unusual case of neuroprotection. Arch Dis Child 2007; 92 (9) 795-796
6 Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet 2001; 103 (3) 226-230
7 Wirojanan J, Kraff J, Hawkins DS , et al. Two boys with fragile x syndrome and hepatic tumors. J Pediatr Hematol Oncol 2008; 30 (3) 239-241
8 Garrè ML, Cama A, Bagnasco F , et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome—a new clinical perspective. Clin Cancer Res 2009; 15 (7) 2463-2471
9 Chi SN, Gardner SL, Levy AS , et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004; 22 (24) 4881-4887
10 Antar LN, Bassell GJ. Sunrise at the synapse: the FMRP mRNP shaping the synaptic interface. Neuron 2003; 37 (4) 555-558
11 Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27 (7) 370-377
12 Coffee B, Ikeda M, Budimirovic DB, Hjelm LN, Kaufmann WE, Warren ST. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am J Med Genet A 2008; 146A (10) 1358-1367
13 Tassone F, Hagerman RJ, Iklé DN , et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999; 84 (3) 250-261
14 Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002; 28 (4) 257-282
15 Fattet S, Haberler C, Legoix P , et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218 (1) 86-94
16 Yokota N, Nishizawa S, Ohta S , et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 2002; 101 (2) 198-201
17 Luo Y, Shan G, Guo W , et al. Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 2010; 6 (4) e1000898
18 Northcott PA, Korshunov A, Witt H , et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29 (11) 1408-1414
19 Baryawno N, Sveinbjörnsson B, Kogner P, Johnsen JI. Medulloblastoma: a disease with disorganized developmental signaling cascades. Cell Cycle 2010; 9 (13) 2548-2554
20 Ellison DW, Dalton J, Kocak M , et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; 121 (3) 381-396
21 Yoon JW, Gilbertson R, Iannaccone S, Iannaccone P, Walterhouse D. Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer 2009; 124 (1) 109-119
22 Fan X, Mikolaenko I, Elhassan I , et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64 (21) 7787-7793
23 Darnell JC, Van Driesche SJ, Zhang C , et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146 (2) 247-261
24 Wlodarski PK, Boszczyk A, Grajkowska W, Roszkowski M, Jozwiak J. Implication of active Erk in the classic type of human medulloblastoma. Folia Neuropathol 2008; 46 (2) 117-122
25 Włodarski P, Grajkowska W, Łojek M, Rainko K, Jóźwiak J. Activation of Akt and Erk pathways in medulloblastoma. Folia Neuropathol 2006; 44 (3) 214-220